This radiotherapy combined with chemotherapy improves the survival rate of colorectal cancer

Share This Post

New research shows that in patients with liver or liver-dominant metastatic colorectal cancer , the addition of selective internal radiation therapy to standard first-line mFOLFOX6 chemotherapy results in a significant increase in the survival of patients with primary tumors on the right.

SIRT, which has been used in Europe since 2003, is an internal radiotherapy using Y-90 resin microspheres (diameters between 20 and 60 microns) delivered in the hepatic artery using a catheter Beta radiation emitting microspheres are preferentially placed in the microvessels around the tumor, minimizing systemic effects.

The SIRFLOX, FOXFIRE and FOXFIRE global studies aimed to evaluate the efficacy and safety of SIRT plus first-line oxaliplatin chemotherapy for unresectable mCRC.

For 554 patients who received chemotherapy plus SIRT and 549 patients who received chemotherapy only, the results showed that the median survival time of the left tumor of mCRC patients in the chemotherapy plus SIRT group was 24.6 months, compared with 26.6 months in the chemotherapy alone group, but SIRT chemotherapy The median survival of mCRC patients with unilateral tumors was 22 months in the group and 17.1 months in the chemotherapy alone group, which was 5 months longer.

At a news conference, Dr. Harpreet Wasan told Imperial College Health Care NHS Trust in the UK that a hypothesis is that the right side cancer not only […] worsens but is more resistant to chemotherapy. They may be more sensitive to radiation therapy, which has a completely different mechanism of action.

Dr. Wasan added that the lack of positive findings in the overall analysis may be due to the inclusion of patients with metastatic cancer outside the liver. He said: “Although SIRT can control liver diseases, it cannot control diseases outside the liver.”

https://www.medicalnewstoday.com/articles/318283.php

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy